Real-world use, safety, and mental health efficacy of regulated psilocybin services in Oregon and Colorado
Preprint
Abstract
Oregon (OR) and Colorado (CO) were the first states to enact regulations for provision of psilocybin with support of licensed ‘facilitators.’ As more states and countries adopt similar policies, informed public policy decisions require that client characteristics and rationale for using psilocybin, psilocybin dosing practices, mental health outcomes, and adverse events are understood. We performed a retrospective observational study of responses for 2363 individuals receiving psilocybin at OR and CO regulated service centers. Clients and facilitators entered data before and after receiving psilocybin, including the Mystical Experience Questionnaire-30 (MEQ-30), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7), and World Health Organization Well-Being Index-5 (WHO-5). Preexisting mental health issues were common (66%) in participants. Psilocybin doses ranged from 1-95 mg, with a mean total of 28·8 mg. We observed improvements of 49% in PHQ-9 scores, 51% in GAD-7 scores, and 22% in WHO-5 scores at two-weeks after dosing. MEQ-30 scores were dose-dependent. Changes in PHQ-9 and GAD-7 scores were not different for psilocybin doses ≤30 mg and >30 mg, and only weakly correlated with MEQ-30 scores. There were 94 mild adverse events during and after dosing, five more serious events not clearly related to treatment, and evidence of possible risk of increased suicidality. Study limitations include open label administration, self-reporting, loss of participants for follow-up, and a short 2-week post-dosing end-point. We conclude that psilocybin services, delivered within these regulated frameworks, is associated with improvements in mental health in real world populations, however, more robust monitoring is needed to ensure safety.Keywords
This publication has 28 references indexed in Scilit:
- Blinding Integrity in Psychedelic Randomized Clinical TrialsJAMA Psychiatry, 2026
- Balancing safety and access in Oregon’s psilocybin servicesInternational Journal of Drug Policy, 2026
- Psychedelic Trips: Travel Within the United States to Use Psychedelic Drugs After LegalizationAnnals of Emergency Medicine, 2025
- Systematic Review of the Use of the WHO-5 Well-Being Index Across Different Disease AreasAdvances in Therapy, 2025
- Adverse Events in Studies of Classic PsychedelicsJAMA Psychiatry, 2024
- Single-Dose Psilocybin Treatment for Major Depressive DisorderJAMA, 2023
- Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trialeClinicalMedicine, 2022
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use DisorderJAMA Psychiatry, 2022
- Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study in Healthy SubjectsClinical Pharmacology & Therapeutics, 2021
- Screening for Depression in Medical Settings with the Patient Health Questionnaire (PHQ): A Diagnostic Meta-AnalysisJournal of General Internal Medicine, 2007